Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort

BACKGROUND: Switching from originator infliximab (IFX) to biosimilar IFX is effective and safe. However, data on multiple switching are scarce. The Edinburgh inflammatory bowel disease (IBD) unit has undertaken three switch programmes: (1) Remicade to CT‐P13 (2016), (2) CT‐P13 to SB2 (2020), and (3)...

Descripción completa

Detalles Bibliográficos
Autores principales: Gros, Beatriz, Plevris, Nikolas, Constantine‐Cooke, Nathan, Lyons, Mathew, O'Hare, Claire, Noble, Colin, Arnott, Ian D., Jones, Gareth‐Rhys, Lees, Charlie W., Derikx, Lauranne A. A. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039791/
https://www.ncbi.nlm.nih.gov/pubmed/36802176
http://dx.doi.org/10.1002/ueg2.12357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039791/
https://www.ncbi.nlm.nih.gov/pubmed/36802176
http://dx.doi.org/10.1002/ueg2.12357

Ejemplares similares